Fragmentation of toxicologically relevant drugs in positive-ion liquid chromatography-tandem mass spectrometry.
about
Recent developments in HPLC analysis of β-blockers in biological samplesIdentification of small molecules using accurate mass MS/MS searchSimultaneous ESI-APCI+ ionization and fragmentation pathways for nine benzodiazepines and zolpidem using single quadrupole LC-MS.In vitro metabolism studies on mephedrone and analysis of forensic cases.Fragmentation of toxicologically relevant drugs in negative-ion liquid chromatography-tandem mass spectrometry.Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes.Tandem mass spectrometry study of p38α kinase inhibitors and related substances.Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC-HR-QTOFMS approach.Simultaneous screening of targeted and non-targeted contaminants using an LC-QTOF-MS system and automated MS/MS library searching.Urinary antihypertensive drug metabolite screening using molecular networking coupled to high-resolution mass spectrometry fragmentationIdentification of promethazine as an amyloid-binding molecule using a fluorescence high-throughput assay and MALDI imaging mass spectrometry.Recent developments in MS for small molecules: application to human doping control analysis.Application of mass spectrometry to hair analysis for forensic toxicological investigations.Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology.In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples.Efficient Sustainable Tool for Monitoring Chemical Reactions and Structure Determination in Ionic Liquids by ESI-MS.The (un)certainty of selectivity in liquid chromatography tandem mass spectrometry.The chemical fate of paroxetine metabolites. Dehydration of radicals derived from 4-(4-fluorophenyl)-3-(hydroxymethyl)piperidine.A tutorial in small molecule identification via electrospray ionization-mass spectrometry: The practical art of structural elucidation.Determination of the psychoactive drugs carbamazepine and diazepam in hospital effluent and identification of their metabolites.Collision-induced dissociation pathways of H1-antihistamines by electrospray ionization quadrupole time-of-flight mass spectrometry.Characterization of hallucinogenic phenethylamines using high-resolution mass spectrometry for non-targeted screening purposes.Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MSn , and LC-HR-MS/MS.Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MSn, and LC-HR-MS/MS.Structural characterization of product ions by electrospray ionization and quadrupole time-of-flight mass spectrometry to support regulatory analysis of veterinary drug residues in foods.
P2860
Q26853476-EED3618D-51F0-4FB7-A2B4-260D5F15CA4AQ29994570-FD1AB336-5EFC-4CFC-A96F-0B8082B2F560Q33458915-456C47A4-8E4C-42F8-9ED8-4E00AFBFB9FEQ34273882-CC94A7B4-12BA-47B0-9ABD-0F1F8ABBA62EQ34350577-85B5D57E-4997-435F-93F1-FE012771F510Q34490537-3C5C5E2F-F78D-4216-A363-39BFAFF96CDBQ34521916-4B8DC198-4A57-4997-92A0-E5CD831678BEQ34748950-BB42F891-E722-4003-B78B-4BB89DC3FAC1Q35168771-76EC873A-B233-4CC6-B7EB-52AAE31F443BQ35258747-46E5ACAF-AEF0-49BE-901C-C96BCE6991BCQ37063195-7CF72322-F30F-4CEF-9DEB-7E55BB057805Q37185672-49D00547-9540-4DC9-B77E-C793C709A91CQ37976443-3625EF5B-BBF0-4D85-9615-7CF7A139A7FEQ38061093-00D3B1FB-841F-40EF-AEE2-5EDC69068538Q38754171-F71570D4-96B3-48EA-97EB-B5AD03C71298Q39115811-D5F053A7-0B73-49B2-8ED2-60B153C33E47Q41872330-2C8F2121-C5D5-4160-9AB5-22EFF8B7B5B6Q44561200-CA91E3A1-3A15-462D-AA1A-88063F0BB92DQ44594481-C0643253-64DA-40D8-8E15-5481DB777BE5Q47614283-0A725345-3764-4C18-9415-D8CCFEF472FDQ47680979-9D33F4C1-03DE-46D8-8AF6-8B2F2EA75979Q48295900-C29D4CFE-7183-4510-91BB-7038ACF9F237Q48299643-40ADB8F7-0979-4A6A-A0E1-FD0CB41A8E71Q48362650-A3C8B00D-7AB4-418F-B939-7C6FE391419BQ53641072-03876867-3DF8-4CA6-8543-90B382C5D790Q53721501-58009DC3-D72D-42C0-A5E3-FF0F5B7680B1
P2860
Fragmentation of toxicologically relevant drugs in positive-ion liquid chromatography-tandem mass spectrometry.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Fragmentation of toxicological ...... aphy-tandem mass spectrometry.
@ast
Fragmentation of toxicological ...... aphy-tandem mass spectrometry.
@en
type
label
Fragmentation of toxicological ...... aphy-tandem mass spectrometry.
@ast
Fragmentation of toxicological ...... aphy-tandem mass spectrometry.
@en
prefLabel
Fragmentation of toxicological ...... aphy-tandem mass spectrometry.
@ast
Fragmentation of toxicological ...... aphy-tandem mass spectrometry.
@en
P2860
P356
P1476
Fragmentation of toxicological ...... aphy-tandem mass spectrometry.
@en
P2093
W M A Niessen
P2860
P304
P356
10.1002/MAS.20332
P577
2011-02-03T00:00:00Z